Why ARK Genomic Revolution ETF (ARKG) Is Up +15% in the Last 30 Days
Key Takeaways
- ARKG has climbed roughly 15% over the trailing 30 days, extending a broad rebound in the genomics theme.
- The fund is up approximately 24% over the trailing three months, recovering sharply from a mid-summer drawdown near $37.50.
- Gains have been concentrated in top positions such as Twist Bioscience, 10x Genomics, Tempus AI, and Personalis.
- ARKG is an actively managed, non-diversified thematic ETF whose top 10 holdings represent roughly 60% of assets.
- Exposure is almost entirely healthcare, making performance highly sensitive to biotech sentiment and interest-rate expectations.
ARK Genomic Revolution ETF (ARKG) Overview and Portfolio Exposure
The ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) that seeks long-term growth of capital. Under normal circumstances it invests at least 80% of its assets in companies tied to the "genomics revolution," spanning areas such as DNA sequencing, gene editing, molecular diagnostics, synthetic biology, and AI-enabled drug discovery. The fund is non-diversified, meaning it can concentrate capital in a relatively small number of positions.
ARKG holds approximately 30 to 35 individual securities, with roughly $2 billion in assets under management (AUM) and a net expense ratio of 0.75%. Its sector allocation is overwhelmingly healthcare, with a modest weighting in adjacent technology names. The largest holdings include Twist Bioscience (TWST), 10x Genomics (TXG), Tempus AI (TEM), CRISPR Therapeutics (CRSP), Personalis (PSNL), and Absci (ABSI), alongside diagnostics names such as Natera (NTRA), Illumina (ILMN), and CareDx (CDNA).
This concentrated, high-beta structure explains much of the fund's recent behavior. Because a handful of small- and mid-cap growth names drive the portfolio, ARKG tends to amplify both upside and downside moves in the genomics and precision-medicine complex.
ARK Genomic Revolution ETF (ARKG) Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ARKG has advanced approximately 15%, rising from a closing level near $47 in early September to roughly $54 as of early October. The move was not uniform: the fund consolidated through the first half of September before accelerating in mid- and late September, punctuated by strong single-session gains and intermittent pullbacks.
The trailing three-month picture is similarly constructive. The fund traded near $43.50 in early July, slipped to a low near $37.50 in late July, and then staged a sustained recovery into October, finishing the period up roughly 24%. This V-shaped pattern indicates a trend-driven rebound rather than a purely range-bound or sideways market, though day-to-day volatility remained elevated throughout.
What Drove ARKG Price in the Last 30 Days
The recent advance has been driven primarily by strength in the fund's largest holdings. Positions such as Twist Bioscience, 10x Genomics, Tempus AI, Personalis, and Absci delivered outsized gains during the period, reflecting renewed investor appetite for genomics, AI-enabled drug discovery, and precision diagnostics. Because the top 10 names account for roughly 60% of the portfolio, concentrated outperformance in even a few of these stocks has a disproportionate effect on the fund's net asset value (NAV).
Broader market conditions also played a role. Growth-oriented and small- to mid-cap biotech equities are highly sensitive to interest-rate expectations and overall risk sentiment, and a more favorable risk appetite helped lift the sector from its summer lows. The recovery in sequencing, gene-editing, and computational biology names points to a rotation back toward high-beta innovation themes after a period of de-risking.
What Drove ARKG Performance Over the Last Quarter
The three-month trend reflects a broader rotation into genomics and precision-medicine equities. After a mid-summer drawdown that pushed ARKG toward $37.50, investor positioning gradually normalized, and the fund's core names re-rated higher as risk appetite improved across growth and biotech sectors.
Longer-term structural themes also supported the move. Continued progress in gene editing, declining costs of DNA sequencing, and the integration of artificial intelligence into drug discovery have kept institutional attention focused on the genomics complex. The fund's concentration in these areas meant that a recovery in sector leadership translated directly into stronger fund performance, while its non-diversified structure amplified both the summer decline and the subsequent rebound.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool surfaces candidates based on momentum, trend, and other quantitative criteria, allowing users to narrow the investable universe more efficiently than manual screening. For investors tracking themes such as genomics and biotechnology, it offers a way to identify emerging opportunities and compare securities across sectors. Explore the AI Screener to build a data-driven approach to market research.
ARKG ETF Outlook: What Investors Should Watch Next
The most important factors for ARKG going forward center on interest-rate expectations, the regulatory environment, and the fundamental progress of its largest holdings. Because the portfolio is dominated by growth-oriented, often unprofitable or early-stage companies, its valuation multiples remain sensitive to shifts in monetary policy and risk appetite.
Investors should monitor clinical trial readouts, product launches, and regulatory decisions affecting gene-editing and diagnostics firms, as well as the pace of commercialization for AI-enabled drug discovery platforms. Fund flows and competition among thematic ETFs may also influence demand. The fund's concentrated, non-diversified structure means it carries elevated volatility and concentration risk, even as it offers direct exposure to the long-term genomics theme. No single catalyst is likely to define the path forward; rather, a combination of macro conditions, sector sentiment, and company-specific milestones will shape performance in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARKG's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 242 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 202 of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 31 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ARKG turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 46 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health